Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Where medicine, business, and public policy intersect.

Literature DB >> 23397413

Where medicine, business, and public policy intersect.

Chantell L Wilson, Stephanie Schultz, Scott A Waldman.

Abstract

Molecular biomarkers are emerging as key indices for the management of patients with cancer and other significant diseases, but their potential has yet to be fully realized. Is there enough collaboration in place to optimize this care revolution?

Entities: Disease Species

Year: 2007 PMID： 23397413 PMCID： PMC3564384

Source DB: PubMed Journal: Biotechnol Healthc ISSN： 1554-169X

18 in total

1. The rocky road to useful cancer biomarkers.

Authors: Jennifer Fisher Wilson
Journal: Ann Intern Med Date: 2006-06-20 Impact factor: 25.391

2. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs.

Authors: J A Wagner; S A Williams; C J Webster
Journal: Clin Pharmacol Ther Date: 2007-01 Impact factor: 6.875

3. Genetic testing oversight.

Authors: Kathy L Hudson
Journal: Science Date: 2006-09-29 Impact factor: 47.728

Review 4. A cost-effectiveness approach to the qualification and acceptance of biomarkers.

Authors: Stephen A Williams; David E Slavin; John A Wagner; Christopher J Webster
Journal: Nat Rev Drug Discov Date: 2006-11 Impact factor: 84.694

5. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.

Authors: Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Barry A Turnbull; Michael E Ross
Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245

6. Cancer biomarkers--an invitation to the table.

Authors: William S Dalton; Stephen H Friend
Journal: Science Date: 2006-05-26 Impact factor: 47.728

7. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245

8. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Authors: H Meijers-Heijboer; B van Geel; W L van Putten; S C Henzen-Logmans; C Seynaeve; M B Menke-Pluymers; C C Bartels; L C Verhoog; A M van den Ouweland; M F Niermeijer; C T Brekelmans; J G Klijn
Journal: N Engl J Med Date: 2001-07-19 Impact factor: 91.245

9. The consensus coding sequences of human breast and colorectal cancers.

Authors: Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal: Science Date: 2006-09-07 Impact factor: 47.728

10. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.

Authors: Annuska M Glas; Marie José Kersten; Leonie J M J Delahaye; Anke T Witteveen; Robby E Kibbelaar; Arno Velds; Lodewyk F A Wessels; Peter Joosten; Ron M Kerkhoven; René Bernards; Johan H J M van Krieken; Philip M Kluin; Laura J van't Veer; Daphne de Jong
Journal: Blood Date: 2004-09-02 Impact factor: 22.113

5 in total

Where medicine, business, and public policy intersect.

1. The rocky road to useful cancer biomarkers.

2. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs.

3. Genetic testing oversight.

Review 4. A cost-effectiveness approach to the qualification and acceptance of biomarkers.

5. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.

6. Cancer biomarkers--an invitation to the table.

7. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

8. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

9. The consensus coding sequences of human breast and colorectal cancers.

10. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.

Review 1. Molecular staging individualizing cancer management.

Review 2. GUCY2C molecular staging personalizes colorectal cancer patient management.

Review 3. Guanylyl cyclase C as a biomarker in colorectal cancer.

Review 4. The economic considerations and implications of the stratification of future oncology therapeutics.

5. Molecular staging of node negative patients with colorectal cancer.